case_images: PMC11442223_01
case_images: The timeline of patients' treatment and efficacy evaluation. CAR-T, Chimeric Antigen Receptor T-cell; Allo-HSCT, allogenic hematopoietic stem cell transplantation; MRD, minimal residual disease.
case_images: fimmu-15-1454614-g001.jpg
case_images: PMC11442223_01_fimmu-15-1454614-g001.jpg
case_images: f1
case_images: The complete treatment process and evaluation of remission for this patient were illustrated in  Figure 1 .
case_images: Clinical data measurements during the infusion of CAR-T cells. (A) Cytometric diagrams depicting the expansion of CAR-T cells within peripheral CD3-positive cells on Day +3 and +9; (B) CAR-T cells expansion variation in peripheral blood; (C-E). The temperature peak, C-reactive protein, and cytokine profiles including IL6, TNF-alpha, and IFN-gamma assessment during the CAR-T cell therapy and allo-HSCT treatment; (F-I). The white blood cells (WBC), neutrophils, hemoglobin, and platelets (PLT) variation during the combination therapy; (J) The morphological detection at pre-lymphodepletion, post-CAR-T cell infusion, and post-HSCT.
case_images: fimmu-15-1454614-g002.jpg
case_images: PMC11442223_01_fimmu-15-1454614-g002.jpg
case_images: f2
case_images: Meanwhile, we investigated the expansion of CAR-T cells during treatment, and observed that the peak proportion of CAR-T cells in peripheral blood CD3 cells occurred on day 7, reaching 21.94% ( Figures 2A, B ). Additionally, the temperature and inflammatory markers including IL6, IFN-gamma, TNF-alpha, and C-reactive protein (CRP) also reached their highest levels on days 7-10 ( Figures 2C-E ). The changes in blood cell counts were illustrated in  Figures 2F-I . The morphological detection variation of this patient was illustrated in  Figure 2J , showcasing the disease status at multiple time points including pre-lymphodepletion, post-CAR-T cell infusion, and post-HSCT.